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Abstract
Making evidence-informed decisions with the aim of improving the health of individuals or populations can be
facilitated by using a systematic approach. While a number of algorithms already exist, and while there is no single
‘right’ way of summarizing or ordering the various elements that should be involved in making such health-related
decisions, an algorithm is presented here that lays out many of the key issues that should be considered, and
which adds a special emphasis on balancing the values of individual patients and entire populations, as well as the
importance of incorporating contextual considerations. Indeed many different types of evidence and value
judgements are needed during the decision-making process to answer a wide range of questions, including (1)
What is the priority health problem? (2) What causes this health problem? (3) What are the different strategies or
interventions that can be used to address this health problem? (4) Which of these options, as compared to the
status quo, has an added benefit that outweighs the harms? (5) Which options would be acceptable to the
individuals or populations involved? (6) What are the costs and opportunity costs? (7) Would these options be
feasible and sustainable in this specific context? (8) What are the ethical, legal and social implications of choosing
one option over another? (9) What do different stakeholders stand to gain or lose from each option? and (10)
Taking into account the multiple perspectives and considerations involved, which option is most likely to improve
health while minimizing harms? This third and final article in the ‘Evidence for Health’ series will go through each
of the steps in the algorithm in greater detail to promote more evidence-informed decisions that aim to improve
health and reduce inequities.
Keywords: Decision-making, Evidence-based medicine, Health equity, Health outcomes, Health policy, Public
health, Research
Background
Making evidence-informed decisions with the aim of
improving the health of individuals or populations
can be facilitated by using a systematic approach [1].
Indeed, there is an entire field of scientific inquiry de-
voted to medical decision-making with a vast number
of different types of algorithms and approaches which
have been proposed for structuring the decision-
making process [2-4]. While there is no single way of
summarizing or ordering the various elements that
should be involved in making such health-related de-
cisions, the following algorithm proposed here lays
out, in a straightforward and non-mathematical way,
many of the key issues that should be considered,
with a strong focus on evidence, values and context
(Fig. 1). The remainder of this third and final article
in the ‘Evidence for Health’ series will go through
each of the steps in the algorithm in greater detail to
promote more evidence-informed and nuanced decisions
that aim to improve health and reduce inequities.* Correspondence: anne.andermann@mail.mcgill.ca
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Define the priority health problem
At the outset, it is helpful to try and identify the prior-
ity health problem (or problems) that, if improved, will
have the greatest impact on health overall [5]. All too
often, a new drug or other intervention is discovered
and people lobby for its implementation and scale-up
when the need for this intervention has not even been
demonstrated and it is unclear whether it will truly have
a widespread impact on the health of a large segment of
the population. Therefore, it is important, in the first in-
stance, that we understand what the true health needs are
in order to be able to then address them in an evidence-
informed way. An objective needs assessment based on
surveillance data of the common causes of morbidity and
premature mortality, combined with a subjective needs as-
sessment based on what the community may consider the
most important priorities, is a good way to start. For ex-
ample, the Tanzania Essential Health Intervention Project
involved a community-based research approach that iden-
tified the true causes of death in two districts in Tanzania
(where most deaths occurred at home, thus rendering
hospital data unreliable). The evidence was then used to
adjust the allocation of the district health budget to be
more in line with the real disease burden. Within 5 years,
a 52% reduction in child mortality was noted and the two
districts reached the related Millennium Development
Goal targets well before 2015 [6].
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Fig. 1 Algorithm for making evidence-informed decisions to improve health [1]
Andermann et al. Health Research Policy and Systems  (2016) 14:16 Page 2 of 8
Understand the underlying causes
It is difficult to tackle a health problemunless there is an
understanding of what causes the problem and where it
would be possible to intervene to mitigate the problem
or ideally to prevent the problem from occurring in the
first place. For a long time, the focus has been on the
proximal causes of health problems commonly known
as the ‘risk factors’ (e.g. smoking, diet, exercise, etc.).
More recently, Sir Michael Marmot coined the phrase
“the causes of the causes” to show how the distribution
of risk factors in a population can be influenced by other
upstream factors known as the “social determinants of
health” [7]. These include factors such as education, em-
ployment, family income, housing and social support,
which influence the health status of populations and can
help to explain why some people are healthy and others
are not [8]. Going even further upstream, Jeff Reading,
formerly Director of the Institute of Aboriginal People’s
Health at the Canadian Institutes for Health Research
described the “causes of the causes of the causes” to show
how the Aboriginal determinants of health underlie the
social determinants, which in turn underlie the distribu-
tion of risk factors, leading to the notion that there can
be proximal, intermediate and distal causes of poor
health [9]:
“What’s the cause of diabetes? Many would say diet and
exercise. The cause of that is poverty and lack of choice
regarding diet and exercise. And the cause of that is
colonization and lack of economic opportunity” [10].
While increasing access to and quality of clinical ser-
vices is clearly important, it cannot be the only approach
to improving health. Rather, a broad range of strategies
are needed, including engaging community leaders, end-
users/consumers and other key stakeholders to create
healthier physical and social environments, as well as
incorporating culturally-adapted and contextualized
solutions to local health problems: “Diabetes is a compli-
cated disease that is nested in the experience of rapid so-
cial and cultural change; thus, its prevention and control
may need new ideas that go beyond an individual ap-
proach in a clinic or hospital ward” [11]. Indeed, changing
these distal determinants will require strong advocacy
for larger social change and legal reforms, which will
only occur if there is buy-in and support from the
highest political levels.
List the options to improve health
Once we have defined the health priorities and have
understood the underlying causes of these problems at
various levels, the next question to ask is “what can we
do about it?” There is always more than one option
available, including the status quo, but how to choose?
The first step is simply identifying what the options are
before attempting to weigh the pros and cons of each.
At a population level, improving health requires a
continuum of strategies (Fig. 2). All too often, when con-
sidering which strategies to choose, people stay within
their comfort zone, screening for risk factors and coun-
selling to promote behaviour change. Whether it is the
prevention of obesity and heart disease or promoting
smoking cessation, there is the notion that people should
be making healthy choices and if they get sick then they
are to blame. Yet, these strategies that focus on the more
proximal causes fail to adequately address the intermedi-
ate and distal causes of poor health. Vineis and Elliot
consider that being a “prisoner to the proximate” is “a
serious mistake” [12]. Mackenbach agrees that we should
not be blaming the individual since “human health and
disease are the embodiment of the successes and failures
of society as a whole” [13]. Moreover, there is a growing
arsenal of strategies (such as intersectoral action, health
in all policies and so forth) that focus on addressing the
upstream determinants and changing the environment
Fig. 2 A continuum of strategies is required to improve health
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to make the healthy choices the easy choices. However,
if these strategies are not included on the ‘list of options’
they will never be chosen. Indeed, working ‘upstream’
may actually bring even greater health improvements
across a large number of areas by acting on the shared
causes of poor health.
Do the added benefits outweigh the harms?
To answer this question, it can be helpful to consider a
number of sub-questions: What is the option being con-
sidered and what is it being compared to (i.e. the current
gold standard or, if there is no gold standard, then the
status quo)? Is there an added benefit at all? And, if so,
what are the added benefits? Is there data on more distal
benefits such as improvements in health outcomes or
only intermediate and proximal measures, such as
changes in patient or health provider behaviours, leaving
one to extrapolate as to the actual impacts of such an
intervention? Are there any harms? And, if so, what are
the harms? Can one say with confidence that there are
no or few harms, or was this something that was not
measured, and therefore an area of uncertainty? How
likely are the benefits and harms and for whom?
To answer these questions, syntheses of the existing
evidence are often used, including systematic reviews
and meta-analyses, which provide an overview of the
existing evidence base. These studies are generally
known as ‘secondary research’ since they do not involve
primary data collection. Instead, the current body of
evidence is used as the starting point, and the study
involves asking a clearly formulated research question,
systematically collecting research evidence around this
question, critically appraising the research studies to
determine which should be included, and finally inte-
grating the results from a wide range of studies, to
thereby present a clearer picture than any individual
study alone can provide [14]. This often serves as an im-
portant anchor to decision-making, particularly in areas
which are highly value-driven and open to debate. How-
ever, it can be difficult to assess the risk-benefit balance
when the harms are not being measured. For instance,
in the case of breast cancer screening, the literature on
mortality benefit came first. As time went on and national
breast screening programs were being implemented, only
then did a new literature start to emerge on the potential
harms of screening, ranging from psychological side
effects and cancer worries [15] to the effects of radiation
related to mammography itself [16]. As a result, this new
evidence provided an opportunity for rethinking the
balance of benefits and harms [17].
Indeed, determining whether there is an added benefit
from the intervention which outweighs the harms often
involves a value judgement and may vary according to
one’s risk tolerance – how much a person wants to avoid
getting the disease being targeted (e.g. breast cancer)
and how much they want to avoid the potential negative
consequences inherent to the intervention itself (e.g.
false positive test result, unnecessary-treatment). Where
there is widespread agreement in a given context that
the added benefits outweigh the harms, we can continue
on with our algorithm; however, if not, then it is back to
the drawing board to look at other options from the list
or to maintain the status quo while working on develop-
ing better options for the future.
Are the options acceptable to those involved?
Before implementing any treatment, program or policy, it
is important to think about those who will be ‘on the re-
ceiving end’. Since we cannot know people’s preferences,
opinions or concerns unless we ask, it is therefore import-
ant that they be involved. Understanding individual and
population preferences, as well as the local context of im-
plementation, is critical to choosing the best option under
the circumstances. No point thinking about costs if the
option is not acceptable in the first place.
For example, some genetic screening programs entail
providing information to be able to make more informed
reproductive choices, and during pregnancy, that could
involve the delicate issue of abortion. In some communi-
ties, due to religious beliefs or cultural values, having a
screening program which includes the possibility of
aborting an unborn child would be quite unacceptable,
even if certain individuals within that community may
want to have that avenue open to them if it turns out
that their child is affected. Thus, the issue of acceptabil-
ity can become quite tricky, especially when it involves
balancing the preferences of individuals with those of
the target population and society overall. Another ex-
ample of where issues of acceptability are particularly
sensitive is when the intervention is delivered to the
entire population and there is no real possibility to ‘opt
out’. For instance, fluoridation of water is widely recog-
nized as a powerful means of improving oral health [18].
Yet, in spite of strong evidence in support of such pro-
grams [19], outcries from vocal opponents have resulted
in millions of people not being protected against dental
decay, and even the halting of certain community-based
water fluoridation programs [20]. Thus, if none of the
options are acceptable, then either further information
can be provided, which may succeed in changing atti-
tudes and generating support for these options, or else it
may be a sign to go back to the drawing board and try
to think up more options.
Calculate costs and opportunity costs
Generally, we find ourselves in a situation where resources
are scarce and, importantly, there is competition with pri-
orities beyond the health sector. So, how do we determine
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which option to choose and which options need to be left
behind (i.e. the opportunity cost)? The Disease Control
Priorities Project [21] and the Choosing Wisely campaign
[22] use effectiveness and cost-effectiveness data to deter-
mine which interventions to scale-up to improve global
health and which interventions to scale back. The cost
effectiveness ratios are generally much lower for prevent-
ive interventions as opposed to curative interventions. For
instance, childhood immunization, insecticide-treated bed
nets for malaria prevention and road traffic safety inter-
ventions (such as speeding laws and speed bumps at busy
intersections) cost only a few dollars per DALY averted,
whereas treating a stroke or heart attack with expensive
‘clot-busting’ medications can cost thousands of dollars
per DALY averted.
Thus, action on the social determinants of health to
prevent problems at the source (i.e. by improving hous-
ing, education, job quality, and so forth) are likely to be
much less expensive as compared to treating people
once they are ill, with all the healthcare costs, missed
work and human suffering that this entails. That being
said, it is often difficult to make such calculations for
interventions that address the social determinants of
health as these tend to involve more complex ‘clusters’
of interventions with less clarity in terms of the specific
costs and outcomes [23]. Indeed, the evidence base relat-
ing to the costs of working more upstream are often
lacking, even if evidence of effectiveness is growing. That
does not mean that we should not be working more
upstream, simply that it is not always easy to estimate
the costs involved. Moreover, when engaging in intersec-
toral action and whole-of-government approaches, it
also remains to be determined which budgetary envelope
these costs should be withdrawn from (i.e. the health
budget or the education budget, the national budget
or the local budget, and so forth). Often, within gov-
ernment, ministries of health tend to have less bar-
gaining power, especially in low- and middle-income
countries, which poses a challenge when it comes to
making health improvement a priority. Further, there can
be “inter-governmental downloading of responsibilities” be-
tween national, district and municipal levels [24]. None-
theless, while cost issues are clearly important, they are
not the only factor in determining the feasibility of one
option over another.
Which options are feasible in this context?
Even if an option is affordable and can be funded using
existing budgets, this does not necessarily mean that it is
feasible since there may be many different kinds of logis-
tical barriers involved, which can often be difficult to
assess in advance. Indeed, just because an intervention
works well in one context or setting does not mean that it
will be applicable and transferable to a different one.
There are many factors that can influence whether it is
likely to expect the same benefits in this new implementa-
tion context [25]; for instance, if the health issue is just as
prevalent and important as in the original study popula-
tion, if there is strong local capacity for implementing the
intervention, if the intervention can be suitably adapted to
the new social and cultural context, and so forth.
Across many parts of Africa and South East Asia,
while it may be possible to afford the cost of vaccines
against childhood diseases – especially as much of the
cost is subsidized by the GAVI alliance through the
Expanded Programme on Immunization – there are
nonetheless various logistical challenges that may re-
main. Vaccination attempts may be thwarted by social or
political unrest, by difficult access to remote areas, and
by lapses in the cold chain [26]. Even if a program is
successfully launched, ongoing sustainability remains a
concern once initial funding is depleted, governments
change and attention turns to other priorities. Piloting
would therefore be needed, sometimes also termed a
‘feasibility study’, to first provide evidence of local effect-
iveness and potential for long-term health gains.
Ethical, legal and social considerations
In some cases, such as end-of-life issues or genetic
screening, the ethical, legal and social issues are quite
apparent [27]. However, it may be even more important
to proceed with caution in situations where such issues
are less obvious and could potentially be overlooked. For
instance, an economic development project that pro-
poses to create more jobs in a rural area may seem
harmless enough. Yet, what if only a small minority
benefit from such an initiative, or even worse, what if
those who benefit least are burdened with most of the
harms? Kass, who developed an ethics framework for
public health, emphasized the importance of ensuring
that interventions not only lead to greater benefit than
harm, but also ensuring that the distribution of benefits
and harms is equitable [28].
Thus, while there may be high quality evidence of effi-
cacy and low cost, this in itself is not sufficient to move
ahead with one option over another. It is important to
carefully consider the ethical, legal and social implica-
tions and to systematically examine who is affected and
in what way, to ensure that everyone is able to share in
the benefits while especially protecting those who are
most vulnerable from the harms. This brings us to our
penultimate step on understanding what the various
stakeholders stand to gain or lose.
What do stakeholders stand to gain or lose?
When considering the potential impacts of any given
option, it is important to look at the different groups
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who could be affected – including various lobby
groups, target populations, innocent bystanders and
the decision-makers themselves – to better appreciate
what each group would gain or lose from implement-
ing this option and what would be the distribution of
the benefits and harms.
Many policies outside the health sector (e.g. tax laws,
parental leave policies, employee disability insurance
schemes, etc.) can have tremendous potential to greatly
benefit and/or harm the health of various groups in soci-
ety. This is the impetus behind the “Health in All Policies”
approach championed by Ilona Kickbush et al. [29], and
also the growing interest in conducting Health Impact
Assessments to help create more evidence-informed
policy [30].
Returning once again to the example of an economic
development project being proposed in a remote com-
munity, it would certainly be unfair if the company
shareholders retained the bulk of the profits while the
workers exposed to potentially hazardous conditions are
paid low wages. Similarly, if community leaders do not
redistribute the wealth and other benefits from deals
signed with the company or at least use the funds to
benefit the local population in some way, that would also
be unfair. Indeed, lack of transparency and profit shar-
ing, lack of equal opportunities for employment, lack of
inclusion and empowerment of those affected, as well as
failure to reinvest profits into health and social services
and tackling the upstream determinants of health (e.g.
through improving education, access to child care, build-
ing social cohesion, etc.) could all lead to worsening
health inequities – in spite of an influx of money and
jobs in the region. Knowing all this, prior to the last step
in the algorithm, there is an opportunity for refining or
even redesigning the proposed option such that the ben-
efits are maximized, the harms are minimized, and the
distribution of benefits and harms is more equitable.
Thus, once these additional safeguards and adjustments
are incorporated, only then is it possible to determine
which options have the greatest potential for improving
health and reducing inequities.
Which options improve health most while minimizing
harms?
At the end of the day, a decision must be made that
integrates all of the evidence from the various steps in
the algorithm and makes a final judgement regarding
whether or not to proceed. The ultimate question is
“which option(s) maximize potential health and social
benefits, minimize potential harms, and ensure that the
distribution of benefits and harms within and between
populations is fair?” Many different types of evidence
and expertise are called upon to make this overarching
decision. Clearly, there will be differences in how one
goes about this depending on whether these are clinical
decisions, population level decisions or global policy
decisions.
Integrating the evidence, values and contextual factors
to come to a final decision is indeed a difficult challenge;
even with all the information at hand, the challenge is
how to take the plunge and transform all of these differ-
ent considerations into a binary choice – “will I choose
this option or that option?” There are examples, espe-
cially in clinical settings, of decision-aids with explicit
value clarification exercises which have been shown to
lead to more informed value-based choices [31] and to
decrease decisional conflict [32]. However, especially in
policy settings, information cannot simply be plugged
into a formula or equation to come up with the best an-
swer. Indeed, there needs to be a structure that involves
the various stakeholders in a deliberative process and, by
following the algorithm outlined in this chapter, they will
be better able to have a more logical and structured
discussion that teases out the complexity involved and
avoids recourse to polemics and entrenched views,
which are often counter-productive. Often, the process
itself is part of the product – by helping to ensure that
different voices are heard, that people feel respected, and
that a fair and transparent process is used to come to a
decision [33], it will be possible to make more reflected
judgements about improving health and reducing in-
equities based on the best available evidence and taking
into account a multitude of complex considerations.
Conclusions
As Michael Marmot once said, “Scientific findings do not
fall on blank minds that get made up as a result. Science
engages with busy minds that have strong views about
how things are and ought to be” [34]. While no decision
is ever free from value judgements, at least using a sys-
tematic approach ensures that the decision is nonethe-
less grounded in the best available evidence, in all its
facets. Additionally, by identifying and making explicit
the various trade-offs and opportunity costs, and by
providing reasons for choosing one option rather than
another, at least there will be the possibility of under-
standing why certain value judgements were made, as
well as being able to challenge the underlying reasons in
future should the context or evidence-base evolve.
It is important to strike a balance between making
decisions that are not at all thought through versus
overthinking every step. The systematic approach can
therefore be helpful to avoid becoming too bogged-
down in the details to see the big picture, or even
worse, being paralyzed by indecision when faced with
a large number of perspectives and trade-offs. In the
end, decisions must be made, since failing to choose
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is simply choosing the status quo. Being transparent
and explicit about the basis for making the decision,
including the quality of evidence, is an important re-
quirement. There are also the very helpful support
tools developed by Lavis et al. [35] which aim to help
in bridging the ‘know-do’ gap.
The goal is therefore to foster a dialogue among stake-
holders that will promote decisions that are more
nuanced, more transparent and, ultimately, more likely
to have an impact on improving health. Nonetheless,
decision-making remains an inherently iterative and often
somewhat disorganized process, especially as we move
towards population-based and global-level decisions.
According to Anderson, a policy analyst, “Public policy is
messy. If you hold on too tightly to your policy formulation
you will wither in this environment. Policy is rarely final
and usually changes with every new administration” [36].
Therefore, all the more reason to ensure that decisions
are informed by evidence and that the key stakeholders
are involved in a meaningful way.
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